{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:54:36Z","timestamp":1788926076221,"version":"build-2803163510"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH110270"],"award-info":[{"award-number":["R01MH110270"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH110270"],"award-info":[{"award-number":["R01MH110270"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH110270"],"award-info":[{"award-number":["R01MH110270"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sistema Nacional de Investigadoras e Investigadores \/ Secretar\u00eda de Ciencia, Humanidades, Tecnolog\u00eda e Innovaci\u00f3n, Mexico"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41386-025-02251-8","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:54:58Z","timestamp":1758815698000},"page":"2063-2071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Concerted elevations of cortical and striatal glutamate and GABA in antipsychotic-free individuals at clinical high-risk for psychosis"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5715-8982","authenticated-orcid":false,"given":"Ragy R.","family":"Girgis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1642","authenticated-orcid":false,"given":"Camilo","family":"de la Fuente-Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Lewis-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0772-4119","authenticated-orcid":false,"given":"Francisco","family":"Reyes-Madrigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie M.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialiang","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangling","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Malacara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Kegeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9452-2245","authenticated-orcid":false,"given":"Dikoma C.","family":"Shungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2251_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301\u20138.","journal-title":"Am J Psychiatry"},{"key":"2251_CR2","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/schbul\/sbs075","volume":"38","author":"B Moghaddam","year":"2012","unstructured":"Moghaddam B, Krystal JH. Capturing the angel in \u201cangel dust\u201d: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull. 2012;38:942\u20139.","journal-title":"Schizophr Bull"},{"key":"2251_CR3","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/schbul\/sbs076","volume":"38","author":"JT Coyle","year":"2012","unstructured":"Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr Bull. 2012;38:920\u20136.","journal-title":"Schizophr Bull"},{"key":"2251_CR4","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/schbul\/sbs069","volume":"38","author":"DC Javitt","year":"2012","unstructured":"Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D. Has an angel shown the way? Etiological and therapeutic implications of the PCP\/NMDA model of schizophrenia. Schizophr Bull. 2012;38:958\u201366.","journal-title":"Schizophr Bull"},{"key":"2251_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jpsychires.2018.07.006","volume":"108","author":"RR Girgis","year":"2019","unstructured":"Girgis RR, Zoghbi AW, Javitt DC, Lieberman JA. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review. J Psychiatr Res. 2019;108:57\u201383.","journal-title":"J Psychiatr Res"},{"key":"2251_CR6","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1038\/mp.2017.249","volume":"23","author":"JA Lieberman","year":"2018","unstructured":"Lieberman JA, Girgis RR, Brucato G, Moore H, Provenzano F, Kegeles L, et al. Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. Mol Psychiatry. 2018;23:1764\u201372.","journal-title":"Mol Psychiatry"},{"key":"2251_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.biopsych.2019.09.022","volume":"87","author":"FA Provenzano","year":"2020","unstructured":"Provenzano FA, Guo J, Wall MM, Feng X, Sigmon HC, Brucato G, et al. Hippocampal Pathology in clinical high-risk patients and the onset of schizophrenia. Biol Psychiatry. 2020;87:234\u201342.","journal-title":"Biol Psychiatry"},{"key":"2251_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neuron.2013.02.011","volume":"78","author":"SA Schobel","year":"2013","unstructured":"Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 2013;78:81\u201393.","journal-title":"Neuron"},{"key":"2251_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1001\/jamapsychiatry.2021.3710","volume":"79","author":"R Basavaraju","year":"2022","unstructured":"Basavaraju R, Guo J, Small SA, Lieberman JA, Girgis RR, Provenzano FA. Hippocampal glutamate and positive symptom severity in clinical high risk for psychosis. JAMA Psychiatry. 2022;79:178\u201379.","journal-title":"JAMA Psychiatry"},{"key":"2251_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199\u2013214.","journal-title":"Arch Gen Psychiatry"},{"key":"2251_CR11","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1038\/npp.2014.143","volume":"39","author":"A Egerton","year":"2014","unstructured":"Egerton A, Stone JM, Chaddock CA, Barker GJ, Bonoldi I, Howard RM, et al. Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis. Neuropsychopharmacology. 2014;39:2891\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"2251_CR12","first-page":"569","volume":"5","author":"C Wenneberg","year":"2020","unstructured":"Wenneberg C, Nordentoft M, Rostrup E, Glenthoj LB, Bojesen KB, Fagerlund B, et al. Cerebral glutamate and gamma-aminobutyric acid levels in individuals at ultra-high risk for psychosis and the association with clinical symptoms and cognition. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5:569\u201379.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"2251_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/ijnp\/pyx076","volume":"21","author":"G Modinos","year":"2018","unstructured":"Modinos G, Simsek F, Horder J, Bossong M, Bonoldi I, Azis M, et al. Cortical GABA in subjects at ultra-high risk of psychosis: relationship to negative prodromal symptoms. Int J Neuropsychopharmacol. 2018;21:114\u201319.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2251_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1017\/S1461145712000314","volume":"16","author":"C de la Fuente-Sandoval","year":"2013","unstructured":"de la Fuente-Sandoval C, Leon-Ortiz P, Azcarraga M, Favila R, Stephano S, Graff-Guerrero A. Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. Int J Neuropsychopharmacol. 2013;16:471\u20135.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2251_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamapsychiatry.2018.3252","volume":"76","author":"MG Bossong","year":"2019","unstructured":"Bossong MG, Antoniades M, Azis M, Samson C, Quinn B, Bonoldi I, et al. Association of hippocampal glutamate levels with adverse outcomes in individuals at clinical high risk for psychosis. JAMA Psychiatry. 2019;76:199\u2013207.","journal-title":"JAMA Psychiatry"},{"key":"2251_CR16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nrn1648","volume":"6","author":"DA Lewis","year":"2005","unstructured":"Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005;6:312\u201324.","journal-title":"Nat Rev Neurosci"},{"key":"2251_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.664535","volume":"9","author":"Y Liu","year":"2021","unstructured":"Liu Y, Ouyang P, Zheng Y, Mi L, Zhao J, Ning Y, et al. A selective review of the excitatory-inhibitory imbalance in schizophrenia: underlying biology, genetics, microcircuits, and symptoms. Front Cell Dev Biol. 2021;9:664535.","journal-title":"Front Cell Dev Biol"},{"key":"2251_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/neuro.02.006.2008","volume":"1","author":"C Kehrer","year":"2008","unstructured":"Kehrer C, Maziashvili N, Dugladze T, Gloveli T. Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia. Front Mol Neurosci. 2008;1:6.","journal-title":"Front Mol Neurosci"},{"key":"2251_CR19","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.biopsych.2017.01.004","volume":"81","author":"JH Krystal","year":"2017","unstructured":"Krystal JH, Anticevic A, Yang GJ, Dragoi G, Driesen NR, Wang XJ, et al. Impaired tuning of neural ensembles and the pathophysiology of schizophrenia: a translational and computational neuroscience perspective. Biol Psychiatry. 2017;81:874\u201385.","journal-title":"Biol Psychiatry"},{"key":"2251_CR20","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41380-021-01297-6","volume":"27","author":"T Nakahara","year":"2022","unstructured":"Nakahara T, Tsugawa S, Noda Y, Ueno F, Honda S, Kinjo M, et al. Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of (1)H-magnetic resonance spectroscopy studies. Mol Psychiatry. 2022;27:744\u201357.","journal-title":"Mol Psychiatry"},{"key":"2251_CR21","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1001\/jamapsychiatry.2021.0380","volume":"78","author":"K Merritt","year":"2021","unstructured":"Merritt K, McGuire PK, Egerton A, Investigators HMiS, Aleman A, Block W, et al. Association of age, antipsychotic medication, and symptom severity in schizophrenia with proton magnetic resonance spectroscopy brain glutamate level: a mega-analysis of individual participant-level data. JAMA Psychiatry. 2021;78:667\u201381.","journal-title":"JAMA Psychiatry"},{"key":"2251_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/schbul\/sbr069","volume":"39","author":"A Marsman","year":"2013","unstructured":"Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-analysis of (1)H-MRS studies. Schizophr Bull. 2013;39:120\u20139.","journal-title":"Schizophr Bull"},{"key":"2251_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.schres.2020.06.028","volume":"226","author":"VJ Sydnor","year":"2020","unstructured":"Sydnor VJ, Roalf DR. A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: implications for studies of psychosis risk. Schizophr Res. 2020;226:61\u201369.","journal-title":"Schizophr Res"},{"key":"2251_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2020.102220","volume":"54","author":"YM Wang","year":"2020","unstructured":"Wang YM, Xiao YH, Xie WL. Metabolite abnormalities in psychosis risk: A meta-analysis of proton magnetic resonance spectroscopy studies. Asian J Psychiatr. 2020;54:102220.","journal-title":"Asian J Psychiatr"},{"key":"2251_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.schres.2019.10.050","volume":"215","author":"C Wenneberg","year":"2020","unstructured":"Wenneberg C, Glenthoj BY, Hjorthoj C, Buchardt Zingenberg FJ, Glenthoj LB, Rostrup E, et al. Cerebral glutamate and GABA levels in high-risk of psychosis states: a focused review and meta-analysis of (1)H-MRS studies. Schizophr Res. 2020;215:38\u201348.","journal-title":"Schizophr Res"},{"key":"2251_CR26","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","volume":"73","author":"K Merritt","year":"2016","unstructured":"Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK. Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies. JAMA Psychiatry. 2016;73:665\u201374.","journal-title":"JAMA Psychiatry"},{"key":"2251_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.biopsych.2022.08.004","volume":"93","author":"M Simmonite","year":"2023","unstructured":"Simmonite M, Steeby CJ, Taylor SF. Medial frontal cortex GABA concentrations in psychosis spectrum and mood disorders: a meta-analysis of proton magnetic resonance spectroscopy studies. Biol Psychiatry. 2023;93:125\u201336.","journal-title":"Biol Psychiatry"},{"key":"2251_CR28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1001\/archgenpsychiatry.2011.1519","volume":"69","author":"LS Kegeles","year":"2012","unstructured":"Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, et al. Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2012;69:449\u201359.","journal-title":"Arch Gen Psychiatry"},{"key":"2251_CR29","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/jamapsychiatry.2013.289","volume":"70","author":"C de la Fuente-Sandoval","year":"2013","unstructured":"de la Fuente-Sandoval C, Leon-Ortiz P, Azcarraga M, Stephano S, Favila R, Diaz-Galvis L, et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry. 2013;70:1057\u201366.","journal-title":"JAMA Psychiatry"},{"key":"2251_CR30","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/npp.2011.65","volume":"36","author":"C de la Fuente-Sandoval","year":"2011","unstructured":"de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, Stephano S, Mamo D, Ramirez-Bermudez J, et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology. 2011;36:1781\u201391.","journal-title":"Neuropsychopharmacology"},{"key":"2251_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.biopsych.2017.09.028","volume":"83","author":"C de la Fuente-Sandoval","year":"2018","unstructured":"de la Fuente-Sandoval C, Reyes-Madrigal F, Mao X, Leon-Ortiz P, Rodriguez-Mayoral O, Jung-Cook H, et al. Prefrontal and striatal gamma-aminobutyric acid levels and the effect of antipsychotic treatment in first-episode psychosis patients. Biol Psychiatry. 2018;83:475\u201383.","journal-title":"Biol Psychiatry"},{"key":"2251_CR32","doi-asserted-by":"publisher","first-page":"pyv105","DOI":"10.1093\/ijnp\/pyv105","volume":"19","author":"C de la Fuente-Sandoval","year":"2015","unstructured":"de la Fuente-Sandoval C, Reyes-Madrigal F, Mao X, Leon-Ortiz P, Rodriguez-Mayoral O, Solis-Vivanco R, et al. Cortico-striatal GABAergic and glutamatergic dysregulations in subjects at ultra-high risk for psychosis investigated with proton magnetic resonance spectroscopy. Int J Neuropsychopharmacol. 2015;19:pyv105.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2251_CR33","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/jamapsychiatry.2023.3157","volume":"80","author":"F Reyes-Madrigal","year":"2023","unstructured":"Reyes-Madrigal F, Gonzalez-Manriquez L, Martinez de Velasco F, Mora-Duran R, Edden RAE, Leon-Ortiz P, et al. Prefrontal gamma-aminobutyric acid levels in never-medicated individuals with chronic schizophrenia. JAMA Psychiatry. 2023;80:1075\u201377.","journal-title":"JAMA Psychiatry"},{"key":"2251_CR34","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1192\/bjp.bp.110.079608","volume":"198","author":"N Aoyama","year":"2011","unstructured":"Aoyama N, Theberge J, Drost DJ, Manchanda R, Northcott S, Neufeld RW, et al. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br J Psychiatry. 2011;198:448\u201356.","journal-title":"Br J Psychiatry"},{"key":"2251_CR35","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/archpsyc.1997.01830220085012","volume":"54","author":"R Bartha","year":"1997","unstructured":"Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1997;54:959\u201365.","journal-title":"Arch Gen Psychiatry"},{"key":"2251_CR36","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jamapsychiatry.2013.2437","volume":"70","author":"NV Kraguljac","year":"2013","unstructured":"Kraguljac NV, White DM, Reid MA, Lahti AC. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry. 2013;70:1294\u2013302.","journal-title":"JAMA Psychiatry"},{"key":"2251_CR37","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1176\/appi.ajp.159.11.1944","volume":"159","author":"J Theberge","year":"2002","unstructured":"Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry. 2002;159:1944\u20136.","journal-title":"Am J Psychiatry"},{"key":"2251_CR38","first-page":"341","volume":"27","author":"Z Yang","year":"2015","unstructured":"Yang Z, Zhu Y, Song Z, Mei L, Zhang J, Chen T, et al. Comparison of the density of gamma-aminobutyric acid in the ventromedial prefrontal cortex of patients with first-episode psychosis and healthy controls. Shanghai Arch Psychiatry. 2015;27:341\u20137.","journal-title":"Shanghai Arch Psychiatry"},{"key":"2251_CR39","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/npp.2016.172","volume":"42","author":"SA Wijtenburg","year":"2017","unstructured":"Wijtenburg SA, Wright SN, Korenic SA, Gaston FE, Ndubuizu N, Chiappelli J, et al. Altered glutamate and regional cerebral blood flow levels in schizophrenia: a (1)H-MRS and pCASL study. Neuropsychopharmacology. 2017;42:562\u201371.","journal-title":"Neuropsychopharmacology"},{"key":"2251_CR40","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1017\/S0033291722001817","volume":"53","author":"XL Cai","year":"2023","unstructured":"Cai XL, Pu CC, Zhou SZ, Wang Y, Huang J, Lui SSY, et al. Anterior cingulate glutamate levels associate with functional activation and connectivity during sensory integration in schizophrenia: a multimodal (1)H-MRS and fMRI study. Psychol Med. 2023;53:4904\u201314.","journal-title":"Psychol Med"},{"key":"2251_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01477-6","volume":"11","author":"BR Godlewska","year":"2021","unstructured":"Godlewska BR, Minichino A, Emir U, Angelescu I, Lennox B, Micunovic M, et al. Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7 T. Transl psychiatry. 2021;11:367.","journal-title":"Transl psychiatry"},{"key":"2251_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.biopsych.2010.08.024","volume":"69","author":"JR Bustillo","year":"2011","unstructured":"Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C, et al. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry. 2011;69:19\u201327.","journal-title":"Biol Psychiatry"},{"key":"2251_CR43","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.schres.2012.06.039","volume":"140","author":"NL Hutcheson","year":"2012","unstructured":"Hutcheson NL, Reid MA, White DM, Kraguljac NV, Avsar KB, Bolding MS, et al. Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging. Schizophr Res. 2012;140:136\u201342.","journal-title":"Schizophr Res"},{"key":"2251_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.schres.2008.11.014","volume":"108","author":"S Tayoshi","year":"2009","unstructured":"Tayoshi S, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, Iga J, et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res. 2009;108:69\u201377.","journal-title":"Schizophr Res"},{"key":"2251_CR45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.schres.2009.11.011","volume":"117","author":"S Tayoshi","year":"2010","unstructured":"Tayoshi S, Nakataki M, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, et al. GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr Res. 2010;117:83\u201391.","journal-title":"Schizophr Res"},{"key":"2251_CR46","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.schres.2009.04.026","volume":"112","author":"N Goto","year":"2009","unstructured":"Goto N, Yoshimura R, Moriya J, Kakeda S, Ueda N, Ikenouchi-Sugita A, et al. Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T proton MRS study. Schizophr Res. 2009;112:192\u20133.","journal-title":"Schizophr Res"},{"key":"2251_CR47","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/mp.2015.34","volume":"21","author":"LM Rowland","year":"2016","unstructured":"Rowland LM, Krause BW, Wijtenburg SA, McMahon RP, Chiappelli J, Nugent KL, et al. Medial frontal GABA is lower in older schizophrenia: a MEGA-PRESS with macromolecule suppression study. Mol Psychiatry. 2016;21:198\u2013204.","journal-title":"Mol Psychiatry"},{"key":"2251_CR48","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.nicl.2014.10.005","volume":"6","author":"A Marsman","year":"2014","unstructured":"Marsman A, Mandl RC, Klomp DW, Bohlken MM, Boer VO, Andreychenko A, et al. GABA and glutamate in schizophrenia: a 7 T (1)H-MRS study. NeuroImage Clin. 2014;6:398\u2013407.","journal-title":"NeuroImage Clin"},{"key":"2251_CR49","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.biopsych.2016.04.007","volume":"81","author":"KN Thakkar","year":"2017","unstructured":"Thakkar KN, Rosler L, Wijnen JP, Boer VO, Klomp DW, Cahn W, et al. 7T Proton magnetic resonance spectroscopy of gamma-aminobutyric acid, glutamate, and glutamine reveals altered concentrations in patients with schizophrenia and healthy siblings. Biol Psychiatry. 2017;81:525\u201335.","journal-title":"Biol Psychiatry"},{"key":"2251_CR50","doi-asserted-by":"crossref","unstructured":"McGlashan TH, Miller TJ, Woods SW, Hoffman RE, Davidson LA. Scale for the assessment of prodromal symptoms and states. In: Miller T, Mednick SA, McGlashan TH, Liberger J, Johannessen JO, editors. Early intervention in psychotic disorders. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2001. p. 135\u201349.","DOI":"10.1007\/978-94-010-0892-1_7"},{"key":"2251_CR51","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1176\/appi.ajp.159.5.863","volume":"159","author":"TJ Miller","year":"2002","unstructured":"Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, et al. Prospective diagnosis of the prodrome for schizophrenia: preliminary evidence of interrater reliability and predictive validity using operational criteria and a structured interview. Am J Psychiat. 2002;159:863\u201365.","journal-title":"Am J Psychiat"},{"key":"2251_CR52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/00005053-200203000-00001","volume":"190","author":"JL Rosen","year":"2002","unstructured":"Rosen JL, Woods SW, Miller TJ, McGlashan TH. Prospective observations of emerging psychosis. J Nerv Ment Dis. 2002;190:133\u201341.","journal-title":"J Nerv Ment Dis"},{"key":"2251_CR53","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/oxfordjournals.schbul.a007040","volume":"29","author":"TJ Miller","year":"2003","unstructured":"Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29:703\u201315.","journal-title":"Schizophr Bull"},{"key":"2251_CR54","unstructured":"WTAR. Wechsler Test of Adult Reading. Texas: Pearson Education, Inc.: 2001."},{"key":"2251_CR55","unstructured":"First MB, Spitzer RL, Gibbon M, and Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington D.C.: American Psychiatric Press, Inc.; 1996."},{"key":"2251_CR56","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.1073\/pnas.90.12.5662","volume":"90","author":"DL Rothman","year":"1993","unstructured":"Rothman DL, Petroff OA, Behar KL, Mattson RH. Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci USA. 1993;90:5662\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2251_CR57","first-page":"1011","volume":"9","author":"N Sailasuta","year":"2001","unstructured":"Sailasuta N, LeRoux P, Hurd R, Wang P, Sachs N, Ketter T. Detection of cerebral gamma-aminobutyric acid (GABA) in bipolar disorder patients and healthy volunteers at 3 T. Proc Int Soc Magn Reson Med. 2001;9:1011.","journal-title":"Proc Int Soc Magn Reson Med"},{"key":"2251_CR58","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/(SICI)1099-1492(199810)11:6<266::AID-NBM530>3.0.CO;2-J","volume":"11","author":"M Mescher","year":"1998","unstructured":"Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998;11:266\u201372.","journal-title":"NMR Biomed"},{"key":"2251_CR59","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/nbm.3539","volume":"29","author":"DC Shungu","year":"2016","unstructured":"Shungu DC, Mao X, Gonzales R, Soones TN, Dyke JP, van der Veen JW, et al. Brain gamma-aminobutyric acid (GABA) detection in vivo with the J-editing (1) H MRS technique: a comprehensive methodological evaluation of sensitivity enhancement, macromolecule contamination and test-retest reliability. NMR Biomed. 2016;29:932\u201342.","journal-title":"NMR Biomed"},{"key":"2251_CR60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.biopsych.2010.08.033","volume":"69","author":"I Valli","year":"2011","unstructured":"Valli I, Stone J, Mechelli A, Bhattacharyya S, Raffin M, Allen P, et al. Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis. Biol Psychiatry. 2011;69:97\u20139.","journal-title":"Biol Psychiatry"},{"key":"2251_CR61","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3915703","volume":"2016","author":"J Wang","year":"2016","unstructured":"Wang J, Tang Y, Zhang T, Cui H, Xu L, Zeng B, et al. Reduced gamma-aminobutyric acid and glutamate+glutamine levels in drug-naive patients with first-episode schizophrenia but not in those at ultrahigh risk. Neural Plast. 2016;2016:3915703.","journal-title":"Neural Plast"},{"key":"2251_CR62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.schres.2013.05.024","volume":"148","author":"N Tandon","year":"2013","unstructured":"Tandon N, Bolo NR, Sanghavi K, Mathew IT, Francis AN, Stanley JA, et al. Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy. Schizophr Res. 2013;148:59\u201366.","journal-title":"Schizophr Res"},{"key":"2251_CR63","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.schres.2013.12.013","volume":"152","author":"EM Poels","year":"2014","unstructured":"Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, et al. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res. 2014;152:325\u201332.","journal-title":"Schizophr Res"},{"key":"2251_CR64","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/mp.2013.136","volume":"19","author":"EM Poels","year":"2014","unstructured":"Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry. 2014;19:20\u20139.","journal-title":"Mol Psychiatry"},{"key":"2251_CR65","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","volume":"69","author":"OD Howes","year":"2012","unstructured":"Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69:776\u201386.","journal-title":"Arch Gen Psychiatry"},{"key":"2251_CR66","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1192\/bjp.bp.113.132308","volume":"204","author":"J Kambeitz","year":"2014","unstructured":"Kambeitz J, Abi-Dargham A, Kapur S, Howes OD. Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. Br J Psychiatry. 2014;204:420\u20139.","journal-title":"Br J Psychiatry"},{"key":"2251_CR67","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","volume":"42","author":"RA McCutcheon","year":"2019","unstructured":"McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci. 2019;42:205\u201320.","journal-title":"Trends Neurosci"},{"key":"2251_CR68","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1001\/jamapsychiatry.2014.2414","volume":"72","author":"M Slifstein","year":"2015","unstructured":"Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry. 2015;72:316\u201324.","journal-title":"JAMA Psychiatry"},{"key":"2251_CR69","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41582-023-00904-0","volume":"20","author":"OD Howes","year":"2024","unstructured":"Howes OD, Bukala BR, Beck K. Schizophrenia: from neurochemistry to circuits, symptoms and treatments. Nat Rev Neurol. 2024;20:22\u201335.","journal-title":"Nat Rev Neurol"},{"key":"2251_CR70","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41537-019-0080-1","volume":"5","author":"K Merritt","year":"2019","unstructured":"Merritt K, Perez-Iglesias R, Sendt KV, Goozee R, Jauhar S, Pepper F, et al. Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. NPJ Schizophr. 2019;5:12.","journal-title":"NPJ Schizophr"},{"key":"2251_CR71","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fpsyt.2013.00151","volume":"4","author":"K Merritt","year":"2013","unstructured":"Merritt K, McGuire P, Egerton A. Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. Front Psychiatry. 2013;4:151.","journal-title":"Front Psychiatry"},{"key":"2251_CR72","first-page":"558","volume":"5","author":"LS Kegeles","year":"2020","unstructured":"Kegeles LS, de la Fuente-Sandoval C. Gamma-aminobutyric acid, glutamate, and cognition in early stages of psychosis: are we closing the gap?. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5:558\u201359.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"2251_CR73","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.neuron.2011.09.027","volume":"72","author":"JS Isaacson","year":"2011","unstructured":"Isaacson JS, Scanziani M. How inhibition shapes cortical activity. Neuron. 2011;72:231\u201343.","journal-title":"Neuron"},{"key":"2251_CR74","doi-asserted-by":"publisher","first-page":"E37","DOI":"10.1503\/jpn.150223","volume":"41","author":"MJ Dubin","year":"2016","unstructured":"Dubin MJ, Mao X, Banerjee S, Goodman Z, Lapidus KA, Kang G, et al. Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy. J Psychiatry Neurosci. 2016;41:E37\u201345.","journal-title":"J Psychiatry Neurosci"},{"key":"2251_CR75","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/mp.2015.83","volume":"21","author":"MS Milak","year":"2016","unstructured":"Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT, et al. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry. 2016;21:320\u20137.","journal-title":"Mol Psychiatry"},{"key":"2251_CR76","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.biopsych.2016.02.009","volume":"80","author":"Z Ren","year":"2016","unstructured":"Ren Z, Pribiag H, Jefferson SJ, Shorey M, Fuchs T, Stellwagen D, et al. Bidirectional homeostatic regulation of a depression-related brain state by gamma-aminobutyric acidergic deficits and ketamine treatment. Biol Psychiatry. 2016;80:457\u201368.","journal-title":"Biol Psychiatry"},{"key":"2251_CR77","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.mri.2007.06.007","volume":"26","author":"N Sailasuta","year":"2008","unstructured":"Sailasuta N, Ernst T, Chang L. Regional variations and the effects of age and gender on glutamate concentrations in the human brain. Magn Reson Imaging. 2008;26:667\u201375.","journal-title":"Magn Reson Imaging"},{"key":"2251_CR78","doi-asserted-by":"crossref","unstructured":"Thomson AR, Hwa H, Pasanta D, Hopwood B, Powell HJ, Lawrence R, et al. The developmental trajectory of 1H-MRS brain metabolites from childhood to adulthood. Cereb Cortex. 2024;34:bhae046.","DOI":"10.1093\/cercor\/bhae046"},{"key":"2251_CR79","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.neuroimage.2013.04.012","volume":"78","author":"F Gao","year":"2013","unstructured":"Gao F, Edden RA, Li M, Puts NA, Wang G, Liu C, et al. Edited magnetic resonance spectroscopy detects an age-related decline in brain GABA levels. Neuroimage. 2013;78:75\u201382.","journal-title":"Neuroimage"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02251-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02251-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02251-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T21:04:28Z","timestamp":1762808668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02251-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":79,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2251"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02251-8","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RRG acknowledges recent expert consulting for Signant Health, Syneos, AlphaSights, Guidepoint, Clearview Healthcare Partners, and Health Monitor for which he received compensation, as well as royalties from books on mental health published by Wipf and Stock and Routledge\/Taylor and Francis. He has also received research support from Bristol Myers Squibb. FR-M has served as a consultant for Boehringer Ingelheim outside the submitted work. No other authors have competing interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}